Galmed Pharmaceuticals Ltd 6-K, filed May 22, 2025
Galmed Pharmaceuticals Ltd. (EOCN)
About this 6-K
Galmed Pharmaceuticals Ltd filed this 6-K on May 22, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of May 2025
001-36345
(Commission File Number)
GALMED PHARMACEUTICALS LTD.
(Exact name of Registrant as specified in its charter)
c/o Meitar Law Offices Abba Hillel Silver Rd.,
Ramat Gan, 5250608
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K contains the quarterly report of Galmed Pharmaceuticals Ltd. (the “Company”), which includes the Company’s unaudited condensed consolidated financial statements for the three months ended March 31, 2025, together with related information and certain other information. The Company is not subject to the requirements to file quarterly or certain other reports under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company does not undertake to file or cause to be filed any such reports in the future, except to the extent required by law.
On May 22, 2025, the Company issued a press release announcing the filing of its financial results for the three months ended March 31, 2025 with the Securities and Exchange Commission. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This Form 6-K is incorporated by reference into the Company’s Registration Statement on Form S-8 (Registration Nos. 333-206292, 333-227441 and 333-284163) and the Company’s Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241).
Financial Statements
GALMED PHARMACEUTICALS LTD.
Condensed Consolidated Balance Sheets (Unaudited)
U.S. Dollars in thousands, except share data and per share data
| As of | As of | |||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 4,767 | $ | 4,652 | ||||
| Short-term deposit | 3,544 | 3,496 | ||||||
| Restricted Cash | 122 | 121 | ||||||
| Marketable debt securities | 7,418 | 7,183 | ||||||
| Other receivables | 447 | 672 | ||||||
| Total current assets | 16,298 | 16,124 | ||||||
| Investment in associate at fair value | 2,119 | 2,119 | ||||||
| Loan to associate | 267 | 257 | ||||||
| Total non-current assets | 2,386 | 2,376 | ||||||
| Total assets | $ | 18,684 | $ | 18,500 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Trade payables | $ | 1,308 | $ | 1,308 | ||||
| Other payables | 499 | 865 | ||||||
| Total current liabilities | 1,807 | 2,173 | ||||||
| Stockholders’ equity | ||||||||
| Ordinary shares par value NIS 1.80 per share; Authorized 50,000,000; Issued and | ||||||||
| outstanding: 2,258,034 shares as of March 31, 2025 and 1,664,884 shares as of December 31, 2024 | 1,029 | 742 | ||||||
| Additional paid-in capital | 217,818 | 216,470 | ||||||
| Accumulated other comprehensive loss | (397 | ) | (416 | ) | ||||
| Accumulated deficit | (201,573 | ) | (200,469 | ) | ||||
| Total stockholders’ equity | 16,877 | 16,327 | ||||||
| Total liabilities and stockholders’ equity | $ | 18,684 | $ | 18,500 | ||||
The accompanying notes are an integral part of the interim Condensed consolidated financial statements.
GALMED PHARMACEUTICALS LTD.
Condensed Consolidated Statements of Operations (Unaudited)
U.S. Dollars in thousands, except share data and per share data
| Three months ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development expenses | $ | 634 | $ | 635 | ||||
| General and administrative expenses | 630 | 766 | ||||||
| Total operating expenses | 1,264 | 1,401 | ||||||
| Financial income, net | (160 | ) | (126 | ) | ||||
| Net loss | $ | 1,104 | $ | 1,275 | ||||
| Basic and diluted net loss per share | $ | 0.62 | $ | 2.10 | (*) | |||
| Weighted-average number of shares outstanding used in computing basic and diluted net loss per share | 1,779,695 | 608,353 | (*) | |||||
The accompanying notes are an integral part of the interim Condensed consolidated financial statements.
(*) Retroactively adjusted (See Note 3.1)
GALMED PHARMACEUTICALS LTD.
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
U.S. Dollars in thousands
| Three months ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Net loss | $ | 1,104 | $ | 1,275 | ||||
| Other comprehensive loss: | ||||||||
| Net unrealized loss (gain) on available for sale securities | (19 | ) | 1 | |||||
| Comprehensive loss | $ | 1,085 | $ | 1,276 | ||||
The accompanying notes are an integral part of the interim Condensed consolidated financial statements.
GALMED PHARMACEUTICALS LTD.
Condensed consolidated Statements of Changes in Stockholders’ Equity (Unaudited)
U.S. Dollars in thousands, except share data and per share data
| Accumulated | ||||||||||||||||||||||||
| Additional | other | |||||||||||||||||||||||
| Ordinary shares | paid-in | Comprehensive | Accumulated | |||||||||||||||||||||
| Shares | Amount | capital | loss | Deficit | Total | |||||||||||||||||||
| Balance - December 31, 2024 | 1,664,884 | 742 | 216,470 | (416 | ) | (200,469 | ) | 16,327 | ||||||||||||||||
| Stock based compensation | - | - | 101 | - | - | 101 | ||||||||||||||||||
| Exercise of RSU’ | 18,263 | 9 | (9 | ) | - | - | - | |||||||||||||||||
| Issuance of ordinary shares in relation to SEPA (**) | 25,000 | 12 | 67 | - | - | 79 | ||||||||||||||||||
| Issuance of SEPA commitment shares (**) | 7,891 | 4 | 12 | - | - | 16 | ||||||||||||||||||
| Issuance of ordinary shares in relation to ATM (***) | 541,996 | 262 | 1,177 | - | - | 1,439 | ||||||||||||||||||
| Unrealized gain from marketable debt securities | - | - | - | 19 | - | 19 | ||||||||||||||||||
| Net loss | - | - | - | - | (1,104 | ) | (1,104 | ) | ||||||||||||||||
| Balance - March 31, 2025 | 2,258,034 | 1,029 | 217,818 | (397 | ) | (201,573 | ) | 16,877 | ||||||||||||||||
| Accumulated | ||||||||||||||||||||||||
| Additional | other | |||||||||||||||||||||||
| Ordinary shares (*) | paid-in | Comprehensive | Accumulated | |||||||||||||||||||||
| Shares | Amount | capital | loss | Deficit | Total | |||||||||||||||||||
| Balance - December 31, 2023 | 573,741 | $ | 209 | $ | 207,076 | $ | (454 | ) | $ | (192,952 | ) | $ | 13,879 | |||||||||||
| Exercise of pre-funded warrants (****) | 80,362 | 40 | (40 | ) | - | - | - | |||||||||||||||||
| Stock-based compensation | - | - | 153 | - | - | 153 | ||||||||||||||||||
| Unrealized loss from marketable debt securities | - | - | - | (1 | ) | - | (1 | ) | ||||||||||||||||
| Net loss | - | - | - | - | (1,275 | ) | (1,275 | ) | ||||||||||||||||
| Balance - March 31, 2024 | 654,103 | $ | 249 | $ | 207,189 | $ | (455 | ) | $ | (194,227 | ) | $ | 12,756 | |||||||||||
(*) Retroactively adjusted (See Note 3.1)
(**) See Note 3.3
(***) See Note 3.4
(****) See Note 3.2
The accompanying notes are an integral part of the interim Condensed consolidated financial statements.
GALMED PHARMACEUTICALS LTD.
Condensed consolidated Statements of Cash Flows (Unaudited)
U.S. Dollars in thousands
| Three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flow from operating activities | ||||||||
| Net loss | $ | (1,104 | ) | $ | (1,275 | ) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities | ||||||||
| Depreciation and amortization | - | 9 | ||||||
| Stock-based compensation expense | 101 | 153 | ||||||
| Amortization of premium on marketable debt securities | 34 | 6 | ||||||
| Interest income from short-term deposits | (48 | ) | (5 | ) | ||||
| Loss (gain) from realization of marketable debt securities | (19 | ) | 1 | |||||
| interest income from loan to associate | (10 | ) | - | |||||
| Finance expenses | - | 1 | ||||||
| Finance expenses related to SEPA (*) | 20 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease in other receivables | 225 | 226 | ||||||
| Decrease in trade payables | - | (496 | ) | |||||
| Decrease in other payables | (366 | ) | (448 | ) | ||||
| Net cash used in operating activities | (1,167 | ) | (1,830 | ) | ||||
| Cash flow from investing activities | ||||||||
| Purchase of available for sale securities | (1,032 | ) | (898 | ) | ||||
| Investment in short term deposits | - | (375 | ) | |||||
| Consideration from sale of available for sale securities | 801 | 1,705 | ||||||
| Net cash provided by investing activities | (231 | ) | 432 | |||||
| Cash flow from financing activities | ||||||||
| Issuance of ordinary shares in relation to ATM (**) | 1,439 | - | ||||||
| Issuance of ordinary shares in relation to SEPA (*) | 75 | - | ||||||
| Net cash provided by financing activities | 1,514 | - | ||||||
| Increase (decrease) in cash and cash equivalents and restricted cash | 116 | (1,398 | ) | |||||
| Cash and cash equivalents and restricted cash at the beginning of the period | 4,773 | 2,978 | ||||||
| Cash and cash equivalents and restricted cash at the end of the period | $ | 4,889 | $ | 1,580 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash received from interest | $ | 171 | $ | 112 | ||||
(*) See Note 3.3
(**) See Note 3.4
The accompanying notes are an integral part of the interim Condensed consolidated financial statements.
GALMED PHARMACEUTICALS LTD.
Notes to Condensed consolidated Financial Statements
Note 1 - Basis of presentation
Galmed Pharmaceuticals Ltd. (the “Company”) was incorporated in Israel on July 31, 2013 and commenced operations on February 2, 2014.
The Company holds three wholly-owned subsidiaries, Galmed International Ltd., which is incorporated in Malta, and Galmed Research and Development Ltd. (“GRD”) and Galtopa Therapeutics Ltd., both of which are incorporated in Israel. In July 2023, GRD established a new wholly-owned subsidiary incorporated under the laws of England and Wales called Galmed Therapeutics UK Limited.
The Company is a biopharmaceutical company focused on the development of Aramchol. The Company has focused almost exclusively on developing Aramchol for the treatment of liver disease and previously was developing Aramchol for Primary Sclerosing Cholangitis, or PSC. The Company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. In addition, as part of the Company’s growth strategy, the Company is actively pursuing opportunities to expand and diversify its product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with the Company’s core expertise in drug development. The Company has an operating history limited to pre-clinical and clinical drug development.
The Company funded its research and development programs and operations to date primarily through proceeds from private placements and public offerings. The Company currently has no products approved for marketing and has not generated any revenue from product sales to date. As of March 31, 2025, the Company had cash and cash equivalents of $4.8 million, restricted cash of $0.1 million, short-term deposits of $3.5 million and marketable debt securities of $7.4 million.
The Company has incurred operating losses in each year since inception. The Company’s loss attributable to holders of its ordinary shares for the three months ended March 31, 2025 and 2024 was approximately $1.1 million and $1.3 million, respectively. As of March 31, 2025, the Company had an accumulated deficit of $201.6 million. Substantially all of its operating losses resulted from costs incurred in connection with the Company’s development program and from general and administrative costs associated with its operations.
The Company will need to raise substantial, additional capital to fund its operations and to develop Aramchol for, and beyond its current development stage and any future commercialization, as well as any additional indications.
Based on the Company’s current operating plan, the Company’s management currently estimates that its cash position will support its current operations as currently conducted for more than 12 months from the date of issuance of these financial statements.
These unaudited interim condensed consolidated financial statements have been prepared as of March 31, 2025 and for the three months period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2024 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on April 2, 2025 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2025.
Note 2 - Summary of significant accounting policies
The significant accounting policies that have been applied in the preparation of the unaudited condensed consolidated interim financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements in connection with its Annual Report on Form 20-F.
Note 3 - Stockholders’ Equity
| 1. | On May 15, 2023, the Company effected a reverse share split of the Company’s ordinary shares at the ratio of 1-for-15, such that each fifteen (15) ordinary shares, par value NIS 0.01 per share, were consolidated into one (1) ordinary share, par value NIS 0.15. On August 29, 2024 the Company effected an additional reverse share split of the Company’s ordinary shares at the ratio of 1-for-12, such that each twelve (12) ordinary shares, par value NIS 0.15 per share, were consolidated into one (1) ordinary share, par value NIS 1.80 per share. As a result, all share and per share amounts prior to the reverse share split were adjusted retroactively for all periods presented in these consolidated financial statements. |
| 2. | On July 18, 2023, the Company sold to investors in a public offering (i) 31,666 ordinary shares, (ii) 435,000 pre-funded warrants to purchase 435,000 ordinary shares (the “Pre-Funded Warrants”), and (iii) 466,666 warrants to purchase 466,666 ordinary shares (the “Investor Warrants”), at a purchase price of $15.0 per share and accompanying Investor Warrant and $14.99 per Pre-Funded Warrant and accompanying Investor Warrant. The net proceeds to the Company were approximately $6.2 million. |
The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per ordinary share. As of December 31, 2024, all of the Pre-Funded Warrants have been exercised.
The Investor Warrants have an exercise price of $15 per ordinary share, are immediately exercisable, and may be exercised until July 18, 2028. During September 2024, a total of 293,333 Investor Warrants have been exercised into 293,333 ordinary shares for a total net proceeds of $4.4 million. As of March 31, 2025 a total of 173,333 warrants are outstanding.
| 3. | On August 30, 2024, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD., a Cayman Islands exempt limited partnership (“YA”). Pursuant to the SEPA, the Company have the right, but not the obligation, to sell to YA from time to time, each such occurrence, an Advance, up to $10.0 million (the “Commitment Amount”), of the Company ordinary shares, during the 36 months following the execution of the SEPA, subject to the restrictions and satisfaction of the conditions in the SEPA. On October 21, 2024, the Company and YA entered into an amendment to the SEPA to increase the Amount of the commitment to $20.0 million of the Company’s ordinary shares. |
As consideration for YA’s irrevocable commitment to purchase the Company’s ordinary shares up to the Commitment Amount, the Company agreed to issue 31,566 ordinary shares (the “Commitment Shares”) to YA and also paid a $15,000 structuring fee to an affiliate of YA. The Commitment Shares shall be issued in four equal installments every 90 calendar days. During the three months ended March 31, 2025, the Company issued a total of 7,891 Commitment Share. The Commitment Shares were recorded as expense in “Finance expenses related to SEPA”, in amounts of $20 thousand.
The Company evaluated the contract that includes the right to require YA to purchase shares of common stock in the future (“put right”) considering the guidance in ASC 815-40, “Derivatives and Hedging — Contracts on an Entity’s Own Equity” and concluded that it is an equity-linked contract that does not qualify for equity classification, and therefore requires fair value accounting and thus meet the definition of a derivative liability. Accordingly, the put right will be measured at fair value at each reporting period, and changes in its fair value will be recognized in the consolidated statement of operations. The Put right is measured under level 2 of the Fair Value hierarchy. The Company analyzed the terms of the freestanding put right and concluded that it has an immaterial value as of March 31, 2025.
As of March 31, 2025, the Company have issued an aggregate of599,55 9 ordinary shares to YA for aggregate gross proceeds of approximately $5.1 million ($4.5 million net of issuance costs).
| 4. | On November 14, 2024, the Company entered into a Capital on Demand Sales Agreement (the “2024 Sales Agreement”) with JonesTrading Institutional Services LLC, (“JonesTrading”). Pursuant to the 2024 Sales Agreement, the Company may offer and sell ordinary shares having an aggregate offering price of up to $8.1 million, from time to time through JonesTrading. As of March 31 2025, the Company sold 541,996 ordinary shares pursuant to the 2024 Sales Agreement, for a total gross consideration of approximately $1.5 million ($1.4 million net). Subsequent to the balance sheet date, the Company sold 2,386,706 ordinary shares pursuant to the 2024 Sales Agreement for a total gross consideration of approximately $5.1 million (approximately $5.0 million net). |
Note 4 – Subsequent events
Regarding additional ordinary shares issued under the 2024 Sales Agreement subsequent to March 31, 2025, see Note 3.4 above.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
All references to “we,” “us,” “our,” “the Company” and “our Company”, in this Form 6-K are to Galmed Pharmaceuticals Ltd. and its subsidiaries, unless the context otherwise requires. All references to “shares” or “ordinary shares” are to our ordinary shares, NIS 1.80 par value per share. All references to “Israel” are to the State of Israel. “U.S. GAAP” means the generally accepted accounting principles of the United States. Unless otherwise stated, all of our financial information presented in this Form 6-K has been prepared in accordance with U.S. GAAP. Any discrepancies in any table between totals and sums of the amounts and percentages listed are due to rounding. Unless otherwise indicated, or the context otherwise requires, references in this Form 6-K to financial and operational data for a particular year refer to the fiscal year of our company ended December 31 of that year.
Our reporting currency and financial currency is the U.S. dollar. In this Form 6-K, “NIS” means New Israeli Shekel, and “$,” “US$” and “U.S. dollars” mean United States dollars.
Cautionary Note Regarding Forward-Looking Statements
This Form 6-K contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements may be included in, among other things, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below:
| ● | the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; | |
| ● | the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; | |
| ● | completion and receiving favorable results of any pre-clinical or clinical trial; | |
| ● | regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; | |
| ● | the commercial launch and future sales of Aramchol and any future product candidates; | |
| ● | our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; | |
| ● | our ability to achieve favorable pricing for Aramchol, or any other product candidate; | |
| ● | third-party payor reimbursement for Aramchol, or any other product candidate; | |
| ● | our estimates regarding anticipated capital requirements and our needs for additional financing; | |
| ● | market adoption of Aramchol or any other product candidate by physicians and patients; | |
| ● | the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; | |
| ● | our ability to obtain and maintain adequate protection of our intellectual property; | |
| ● | the possibility that we may face third-party claims of intellectual property infringement; | |
| ● | our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; | |
| ● | our ability to establish adequate sales, marketing and distribution channels; | |
| ● | intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; | |
| ● | our expectations regarding licensing, acquisitions and strategic operations; | |
| ● | current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; | |
| ● | our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; |
| ● | security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel; and | |
| ● | those factors referred to in “Item 3.D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects” in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on April 2, 2025. |
We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on April 2, 2025, in greater detail under the heading “Risk Factors” and elsewhere in the Annual Report and this Form 6-K. Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events.
All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this Report on Form 6-K. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.
Overview
We are a biopharmaceutical company focused on the development of Aramchol. Historically, we have focused almost exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis.
We are currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.
To date, we have not generated revenue from the sale of any product, excluding the licensing revenue we recorded in connection with the Samil Agreement, and we do not expect to generate any significant revenue other than the amortization of the upfront payments under the license agreement with Samil and of the subsequent royalties and/or milestones that may be earned in connection with the Samil Agreement or potential other license Agreements, unless and until we commercialize Aramchol, or license the product to additional third parties. As of March 31, 2025, we had an accumulated deficit of approximately $201.6 million.
Our financing activities are described below under “Liquidity and Capital Resources.” Obtaining approval of an NDA, MMA, or other similar application is an extensive, lengthy, expensive and uncertain process, and the FDA, EMA, MHRA and other regulatory agencies may delay, limit or deny approval of Aramchol or any other product candidate.
Financial Overview
To date, we have funded our operations primarily through proceeds from private placements and public offerings. On March 31, 2025, we had current assets of $16.3 million, which includes cash and cash equivalents of $4.8 million, short term deposit of $3.5 million, marketable debt securities of $7.4 million, other receivables of $0.4 million and restricted cash of $0.1 million. This compares with current assets of $16.1 million on December 31, 2024, which includes cash and cash equivalents of $4.7 million, short term deposit of $3.5 million, marketable debt securities of $7.2 million, other receivables of $0.7 million and restricted cash of $0.1 million. We believe that such existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this Report on Form 6-K. However, significant additional funding will be necessary to fund our ongoing research and development work and to advance our product candidates through regulatory approval and into commercialization, if approved. We intend to obtain additional funding through debt or equity financings, governmental grants or through entering into collaborations, strategic alliances or license agreements to increase the funds available to support our operating and capital needs. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to Aramchol, and/or our other pre-clinical and clinical programs. This may raise substantial doubts about our ability to continue as a going concern.
Costs and Operating Expenses
Our current costs and operating expenses consist of two components: (i) research and development expenses; and (ii) general and administrative expenses.
Research and Development Expenses
Our research and development expenses consist primarily of outsourced development expenses, salaries and related personnel expenses and fees paid to external service providers, patent-related legal fees, costs of pre-clinical studies and clinical trials and drug and laboratory supplies. We account for all research and development expenses as they are incurred. We expect our research and development expense to remain one of our primary expenses in the near future as we continue to develop Aramchol. Increases or decreases in research and development expenditures are primarily attributable to the number and/or duration of the pre-clinical and clinical studies that we conduct.
We expect that a substantial amount of our research and development expense in the future will be incurred in support of our current and anticipated pre-clinical and clinical development projects. Due to the inherently unpredictable nature of pre-clinical and clinical development studies, we are unable to estimate with any certainty the costs we will incur in the continued development of Aramchol and other product candidate. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We currently expect to continue testing Aramchol in pre-clinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for Aramchol.
The lengthy process of completing clinical trials and seeking regulatory approval for Aramchol requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.
General and Administrative Expenses
General and administrative expenses consist primarily of compensation for employees in executive and operational roles, including finance/accounting, legal and other operating positions in connection with our activities. Our other significant general and administrative expenses include non-cash stock-based compensation costs and facilities costs (including the rental expense for our offices in Tel Aviv, Israel), professional fees for outside accounting and legal services, travel costs, investors relations, insurance premiums and depreciation.
General and administrative expenses also consist of costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs.
Financial income, net
Our financial income, net consists mainly of interest income from marketable debt securities, expenses that we incurred in establishing the SEPA, which includes ordinary shares to the equity line provider, and foreign currency gains. Our financial expenses consist of fees associated with banking activities and losses from realization of marketable debt securities.
Results of Operations
The table below provides our results of operations for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024.
| Three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| (unaudited) | ||||||||
| (In thousands, except per share data) | ||||||||
| Research and development expenses | 634 | 635 | ||||||
| General and administrative expenses | 630 | 766 | ||||||
| Total operating expenses | 1,264 | 1,401 | ||||||
| Financial income, net | (160 | ) | (126 | ) | ||||
| Net loss | 1,104 | 1,275 | ||||||
| Other comprehensive loss (profit): | (19 | ) | 1 | |||||
| Comprehensive loss | 1,085 | 1,276 | ||||||
| Basic and diluted net loss per share | $ | 0.62 | $ | 2.10 | ||||
Research and Development Expenses
Our research and development expenses amounted to approximately $0.6 million during the three months ended March 31, 2025, representing no change compared to approximately $0.6 million for the comparable period in 2024.
General and Administrative Expenses
Our general and administrative expenses amounted to approximately $0.6 million during the three months ended March 31, 2025, representing a decrease of approximately $0.1 million, or 17%, compared to approximately $0.8 million for the comparable period in 2024. The decrease in general and administrative expenses for the three months ended March 31, 2025 resulted primarily from a decrease in professional services expenses.
Operating Loss
As a result of the foregoing, for the three months ended March 31, 2025, our operating loss was approximately $1.3 million, representing a decrease of approximately $0.1 million, or 10%, as compared to approximately $1.4 million for the comparable period in 2024.
Financial income, Net
Our financial income, net amounted to approximately $0.2 million during the three months ended March 31, 2025, compared to $0.1 million for the comparable period in 2024. The change is considered to be immaterial.
The financial income, net for the three months ended March 31, 2025 primarily relates to interest income from marketable debt securities and exchange rate income.
Net Loss
As a result of the foregoing, for the three months ended March 31, 2025, our net loss was approximately $1.1 million, representing a decrease of approximately $0.2 million, or 13%, as compared to approximately $1.3 million for the comparable period in 2024.
Liquidity and Capital Resources
To date, we have funded our operations primarily through proceeds from private placements and public offerings and we have incurred substantial losses since our inception. As of March 31, 2025, we had an accumulated deficit of approximately $201.6 million and positive working capital (current assets less current liabilities) of approximately $14.5 million. We expect that operating losses will continue for the foreseeable future.
As of March 31, 2025, we had cash and cash equivalents of approximately $4.8 million, short term deposits of $3.5 million, restricted cash of approximately $0.1 million and marketable debt securities of approximately $7.4 million invested in accordance with our investment policy, totaling approximately $15.9 million, as compared to approximately $4.7 million, $3.5 million, $0.1 million and $7.2 million as of December 31, 2024, respectively, totaling approximately $15.5 million. The increase is considered to be immaterial.
We had negative cash flow from operating activities of approximately $1.2 million for the three months ended March 31, 2025, as compared to negative cash flow from operating activities of approximately $1.8 million for the three months ended March 31, 2024. The negative cash flow from operating activities for the three months ended March 31, 2025 is mainly attributable to our net loss of approximately $1.1 million.
We had negative cash flow from investing activities of approximately $0.2 million for the three months ended March 31, 2025, as compared to a positive cash flow of approximately $0.4 million for the three months ended March 31, 2024. The negative cash flow from investing activities for the three months ended March 31, 2025 was primarily due to the net purchase of available for sale securities.
We had positive cash flow from financing activities of approximately $1.5 million for the three months ended March 31, 2025, as compared to no cash flow financing activities for the three months ended March 31, 2024. The positive cash flow from financing activities for the three months ended March 31, 2025 was primarily due to issuance of shares in relation to the SEPA (as defined below) and 2024 Sales Agreement (as defined below)
On August 30, 2024, we entered into a Standby Equity Purchase Agreement, or SEPA, with YA II PN, LTD., a Cayman Islands exempt limited partnership, or YA. Pursuant to the SEPA, we have the right, but not the obligation, to sell to YA from time to time, each such occurrence, an Advance, up to $10.0 million, or the Initial Commitment Amount, of our ordinary shares, during the 36 months following the execution of the SEPA, subject to the restrictions and satisfaction of the conditions in the SEPA. On October 21, 2024, we and YA entered into an amendment to the SEPA to increase the Initial Commitment Amount to $20.0 million of our ordinary shares. At our option, the ordinary shares would be purchased by YA from time to time at a price equal to 97% of the lowest of the three daily VWAPs (as hereinafter defined) during a three consecutive trading day period commencing on the date that we, subject to certain limitations, deliver a notice to YA that we are committing YA to purchase such ordinary shares, or the Advance Shares. We may also specify a certain minimum acceptable price per share in each Advance. “VWAP” means, for any trading day, the daily volume weighted average price of our ordinary shares for such trading day on the Nasdaq Stock Market during regular trading hours as reported by Bloomberg L.P. As consideration for YA irrevocable commitment to purchase our ordinary shares up to the Initial Commitment Amount, we agreed to issue 31,566 ordinary shares, or the Commitment Shares, to YA and also paid a $15,000 structuring fee to an affiliate of YA. The Commitment Shares shall be issued in four equal installments, of which 7,892 Commitment Shares were issued on the date of execution of the SEPA and the remaining 23,674 Commitment Shares will be issued in three equal installments 90 calendar days following the due date of the immediately preceding installment until all four installments have been issued. As of the date of this Report on Form 6-K, we have issued an aggregate of 607,450 ordinary shares to YA consisting of (i) 23,675 ordinary shares that we issued to YA as consideration for YA’s irrevocable commitment to purchase our ordinary shares up to the Commitment Amount and (ii) 583,775 ordinary shares represented that we sold to YA as Advance Shares for aggregate gross proceeds of approximately $4.4 million. As of March 31, 2025, we have issued an aggregate of 599,559 ordinary shares to YA for aggregate gross proceeds of approximately $5.1 million.
On November 14, 2024, we entered into a Capital on Demand Sales Agreement, or the 2024 Sales Agreement, with JonesTrading Institutional Serviecs LLC, or JonesTrading. Pursuant to the 2024 Sales Agreement, we may offer and sell our ordinary shares having an aggregate offering price of up to $8.1 million, from time to time through JonesTrading. JonesTrading will receive a commission equal to 3.0% of the gross proceeds from the sale of the ordinary shares and will be reimbursed for certain specified expenses in connection with entering into the Sales Agreement. As of March 31 2025, we sold 541,996 ordinary shares pursuant to the 2024 Sales Agreement, for a total net consideration of approximately $1.4 million. Subsequent to March 31, 2025, we sold 2,386,706 ordinary shares pursuant to the 2024 Sales Agreement for a total net consideration of approximately $5.0 million
Although we provide no assurance, we believe that our existing funds will be sufficient to continue our business and operations as currently conducted for more than 12 months from the date of issuance of this Report on Form 6-K. However, significant additional funding will be necessary to fund ongoing research and development work, to advance our product candidates through regulatory approval and into commercialization, if approved. We intend to obtain additional funding through debt or equity financings, governmental grants or through entering into collaborations, strategic alliances or license agreements to increase the funds available to support our operating and capital needs. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining additional financing on terms acceptable to us. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development plans for, or commercialization efforts with respect to Aramchol, and/or our other pre-clinical and clinical programs. This may raise substantial doubts about our ability to continue as a going concern.
The extent of our future capital requirements will depend on many other factors, including:
| ● | the progress and costs of our pre-clinical studies, clinical trials and other research and development activities;; |
| ● | the regulatory pathway of Aramchol or any other product candidate; |
| ● | the scope, prioritization and number of our clinical trials and other collaboration research and development programs; |
| ● | the amount of revenues and contributions we receive under future licensing, development and commercialization arrangements with respect to Aramchol or any other product candidate; |
| ● | the costs of the development and expansion of our operational infrastructure; |
| ● | the costs and timing of obtaining regulatory approval for Aramchol or any other product candidate; |
| ● | the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under our potential future licensing agreements; |
| ● | the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; |
| ● | the costs and timing of securing manufacturing arrangements for clinical or commercial production; |
| ● | the costs of contracting with third parties to provide sales and marketing capabilities for us; |
| ● | the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or platforms; |
| ● | the magnitude of our general and administrative expenses; |
| ● | any cost that we may incur under future in- and out-licensing arrangements relating to Aramchol or any other product candidate; |
| ● | market conditions; |
| ● | our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; |
| ● | our ability to identify, evaluate and complete any strategic alternative that yields value for our shareholders; and |
| ● | the impact of the security situation in Israel, which may exacerbate the magnitude of the factors discussed above. |
Trend Information
We are a development stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative of future operating results or financial conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.
Controls and Procedures
As a “foreign private issuer”, we are only required to conduct the evaluations required by Rules 13a-15(b) and 13a-15(d) of the Exchange Act as of the end of each fiscal year and therefore have elected not to provide disclosure regarding such evaluations at this time.
Risks Factors
Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Report on Form 6-K, including our unaudited condensed consolidated financial statements and accompanying notes, and the additional information in the other reports we file with the Securities and Exchange Commission along with the risks described in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024. These risks may result in material harm to our business and our financial condition and results of operations. In this event, the market price of our ordinary shares may decline and you could lose part or all of your investment. We have described below those risks that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 20-F for the fiscal year ended December 31, 2024.
Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.
Our executive office is located in Ramat Gan, Israel. In addition, certain of our key employees, officers and directors are residents of Israel. Accordingly, political, economic and military conditions in the Middle East may affect our business directly. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel and its neighboring countries and terrorist organizations active in the region, including Hamas (an Islamist militia and political group in the Gaza Strip) and Hezbollah (an Islamist militia and political group in Lebanon).
In October 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians and soldiers. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks.
In addition, since the commencement of these events, there have been continued hostilities along Israel’s northern border with Lebanon (with the Hezbollah terror organization) and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. Israel has carried out a number of targeted strikes on sites belonging to these terror organizations. In October 2024, Israel began limited ground operations against Hezbollah in Lebanon, culminating in a ceasefire agreed to between Israel and Lebanon in November 2024, the results of which are uncertain. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel. These situations may potentially escalate in the future to more violent events which may affect Israel and us. Such clashes may escalate in the future into a greater regional conflict.
In connection with the Israeli security cabinet’s declaration of war against Hamas and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate military service. Although many of such military reservists have since been released, they may be called up for additional reserve duty, depending on developments in the war in Gaza and along Israel’s other borders. While none of our employees in Israel have been called to active military duty, we rely on service providers located in Israel and have entered into certain agreements with Israeli counterparties. Employees of such service providers or contractual counterparties may be called for service in the current or future wars or other armed conflicts with Hamas as well as the other pending or future armed conflicts in which Israel is or may become engaged, and such persons may be absent for an extended period of time. As a result, our operations may be disrupted by such absences, which disruption may materially and adversely affect our business and results of operations.
While our executive offices are located in Ramat Gan, Israel, which is not near Israel’s borders where the main hostilities have taken place and none of our employees have been called into military reserve duty, to help mitigate the effects of Israel’s war with Hamas, we took several measures, including work-from-home measures and have a business continuity plan.
Disruptions that could severely impact our business, clinical trials, and supply chains, include:
| ● | limitations on employee resources that would otherwise be focused on the conduct of our business including because of military reserve duty call-ups in the future that impact our employees and the affect the current security situation in Israel on the productivity of our employees and external partners; |
| ● | delays in necessary interactions with vendors, local regulators, and other important agencies and contractors due to limitations in employee resources; and |
| ● | impacts from prolonged remote work arrangements, such as increased cybersecurity risks and strains on our business continuity plans. |
The intensity and duration of the current security situation in Israel is difficult to predict, as are such war’s economic implications on the Company’s business and operations, on Israel’s economy in general, on the trading price of shares of our ordinary shares and could impact our ability to raise additional capital on a timely basis or at all. These events may be intertwined with wider macroeconomic indications of a deterioration of Israel’s economic standing that may involve further downgrade in Israel’s credit rating by rating agencies, which may have a material adverse effect on the Company and its ability to effectively conduct its operations. If the ceasefire declared collapses or a new war commences or hostilities expand to other fronts, our operations may be adversely affected. The impact of the current war between Israel and Hamas may also have the effect of heightening many of the other risks described in this section and in the “Risk Factors” section of our Annual Report on Form 20-F for the fiscal year ended December 31, 2024.
In addition, some countries around the world restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies if hostilities in Israel or political instability in the region continue or increase. In addition, there have been increased efforts by countries, activists and organizations to cause companies and consumers to boycott Israeli goods and services. In addition, in January 2024 the International Court of Justice, or ICJ, issued an interim ruling in a case filed by South Africa against Israel in December 2023, making allegations of genocide amid and in connection with the war in Gaza, and ordered Israel, among other things, to take measures to prevent genocidal acts, prevent and punish incitement to genocide, and take steps to provide basic services and humanitarian aid to civilians in Gaza. There are concerns that companies and businesses will terminate, and may have already terminated, certain commercial relationships with Israeli companies following the ICJ decision. The foregoing efforts by countries, activists and organizations, particularly if they become more widespread, as well as the ICJ rulings and future rulings and orders of other tribunals against Israel (if handed), may materially and adversely impact our business, clinical trials, and supply chains.
Furthermore, following Hamas’ attack on Israel and Israel’s security cabinet declaration of war against Hamas, the Houthi movement, which controls parts of Yemen has launched attacks on Israeli-controlled or owned ships in the Red Sea, resulting in shipping companies rerouting their cargo ships or ceasing shipments to Israel in the case of the latter. The hostilities with Hamas, Hezbollah, the Houthi movement and other terrorist organizations, include and may include terror, missile and drone attacks. In the event that our facilities are damaged as a result of hostile actions, or hostilities otherwise disrupt our ongoing operations, our ability to deliver or provide products and services in a timely manner to meet our contractual obligations towards customers and vendors could be materially and adversely affected. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could have a material adverse effect on our business and could make it more difficult for us to raise capital. Our insurance policies do not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations.
Finally, political conditions within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the Israeli government pursued extensive changes to Israel’s judicial system, which sparked extensive political debate and unrest. In response to such initiative, many individuals, organizations and institutions, both within and outside of Israel, voiced concerns that the proposed changes may negatively impact the business environment in Israel including due to reluctance of foreign investors to invest or transact business in Israel, as well as to increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in security markets and other changes in macroeconomic conditions. If such changes to Israel’s judicial system are again pursued by the government and approved by the parliament, this may have an adverse effect on our business, our results of operations and our ability to raise additional funds, if deemed necessary by our management and board of directors.
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release, dated May 22, 2025. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Galmed Pharmaceuticals Ltd. | ||
| Date: May 22, 2025 | By: | /s/ Allen Baharaff |
| Allen Baharaff | ||
| President and Chief Executive Officer | ||
Exhibit 99.1
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
TEL AVIV, Israel, May 22, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications, reports financial results for the three months ended March 31, 2025 and recent developments.
Key Recent Developments
| ● | Announced First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models | |
| ● | Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation | |
| ● | Raised $6.5 million since the beginning of 2025. Company’s current cash balance is $20.1 million |
Financial Summary – First Quarter 2025 vs. First Quarter 2024*:
| ● | Cash and cash equivalents, short term deposits, restricted cash and marketable debt securities totaled approximately $15.9 million as of March 31, 2025, compared to approximately $15.4 million at December 31, 2024. During May 2025, the Company raised an additional $5.0 million. As a result, as of the date hereof, the Company’s current cash balance is approximately $20.1 million. | |
| ● | Net loss amounted to approximately $1.1 million, or $0.62 per share, for the three months ended March 31, 2025, compared to a net loss of approximately $1.3 million, or $2.76 per share, for the three months ended March 31, 2024. | |
| ● | Research and development expenses amounted to approximately $0.6 million for the three months ended March 31, 2025, compared to approximately $0.6 million for the three months ended March 31, 2024. | |
| ● | General and administrative expenses amounted to approximately $0.6 million for the three months ended March 31, 2025, compared to approximately $0.8 million for the three months ended March 31, 2024. The decrease in general and administrative expenses for the three months ended March 31, 2023 resulted primarily from a decrease in professional services expenses. | |
| ● | Financial income, net amounted to approximately $0.2 million for the three months ended March 31, 2025, compared to financial income of $0.1 million for the three months ended March 31, 2024. |
About Galmed Pharmaceuticals Ltd.
We are a biopharmaceutical company focused on the development of Aramchol. We have focused almost exclusively on developing Aramchol for the treatment of liver disease and we are currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.
Forward-Looking Statements:
Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our product development efforts, business, financial condition, results of operations, strategies or prospects, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believes or anticipate will or may occur in the future. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the development and approval of the use of Aramchol or any other product candidate for indications outside of non-alcoholic steatohepatitis, or NASH, also known as metabolic dysfunction-associated steatohepatitis, or MASH, and fibrosis or in combination therapy; the timing and cost of any pre-clinical or clinical trials of Aramchol or any other product candidate we develop; completion and receiving favorable results of any pre-clinical or clinical trial; regulatory action with respect to Aramchol or any other product candidate by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Authority, or EMA, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; the commercial launch and future sales of Aramchol and any future product candidates; our ability to comply with all applicable post-market regulatory requirements for Aramchol, or any other product candidate in the countries in which we seek to market the product; our ability to achieve favorable pricing for Aramchol, or any other product candidate; third-party payor reimbursement for Aramchol, or any other product candidate; our estimates regarding anticipated capital requirements and our needs for additional financing; market adoption of Aramchol or any other product candidate by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol or any other product candidate; our ability to obtain and maintain adequate protection of our intellectual property; the possibility that we may face third-party claims of intellectual property infringement; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; our ability to establish adequate sales, marketing and distribution channels; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; our expectations regarding licensing, acquisitions and strategic operations; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; our ability to maintain the listing of our ordinary shares on The Nasdaq Capital Market; and security, political and economic instability in the Middle East that could harm our business, including due to the current security situation in Israel. We believe these forward-looking statements are reasonable; however, these statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on April 2, 2025 in greater detail under the heading “Risk Factors.” Given these uncertainties, you should not rely upon forward-looking statements as predictions of future events. All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date hereof and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.
* This unaudited preliminary financial information regarding the company’s financial results for the three months and quarter ended March 31, 2025, is based upon the estimates and subject to completion of the company’s quarter-end financial results. Moreover, this financial information has been prepared solely on the basis of currently available information by, and is the responsibility of, management. The company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to such preliminary estimates or the accounting treatment thereof and does not express an opinion or any other form of assurance with respect thereto. This preliminary financial information is not a comprehensive statement of the company’s financial results for this period.
GALMED PHARMACEUTICALS LTD.
Consolidated Balance Sheets
U.S. Dollars in thousands, except share data and per share data
| As of | As of | |||||||
| March 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 4,767 | $ | 4,652 | ||||
| Short-term deposit | 3,544 | 3,496 | ||||||
| Restricted Cash | 122 | 121 | ||||||
| Marketable debt securities | 7,418 | 7,183 | ||||||
| Other receivables | 447 | 672 | ||||||
| Total current assets | 16,298 | 16,124 | ||||||
| Investment in associate at fair value | 2,119 | 2,119 | ||||||
| Loan to associate | 267 | 257 | ||||||
| Total non-current assets | 2,386 | 2,376 | ||||||
| Total assets | $ | 18,684 | $ | 18,500 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities | ||||||||
| Trade payables | $ | 1,308 | $ | 1,308 | ||||
| Other payables | 499 | 865 | ||||||
| Total current liabilities | 1,807 | 2,173 | ||||||
| Stockholders’ equity | ||||||||
| Ordinary shares par value NIS 1.80 per share; Authorized 50,000,000; Issued and outstanding: 2,258,034 shares as of March 31, 2025 and 1,664,884 shares as of December 31, 2024 | 1,029 | 742 | ||||||
| Additional paid-in capital | 217,818 | 216,470 | ||||||
| Accumulated other comprehensive loss | (397 | ) | (416 | ) | ||||
| Accumulated deficit | (201,573 | ) | (200,469 | ) | ||||
| Total stockholders’ equity | 16,877 | 16,327 | ||||||
| Total liabilities and stockholders’ equity | $ | 18,684 | $ | 18,500 | ||||
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Operations (Unaudited)
U.S. Dollars in thousands, except share data and per share data
| Three months ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development expenses | $ | 634 | $ | 635 | ||||
| General and administrative expenses | 630 | 766 | ||||||
| Total operating expenses | 1,264 | 1,401 | ||||||
| Financial income, net | (160 | ) | (126 | ) | ||||
| Net loss | $ | 1,104 | $ | 1,275 | ||||
| Basic and diluted net loss per share | $ | 0.62 | $ | 2.10 | (*) | |||
| Weighted-average number of shares outstanding used in computing basic and diluted net loss per share | 1,779,695 | 608,353 | (*) | |||||
(*) Retroactively adjusted to reflect the reverse split.
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Cash Flows (Unaudited)
U.S. Dollars in thousands
| Three months ended March 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flow from operating activities | ||||||||
| Net loss | $ | (1,104 | ) | $ | (1,275 | ) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities | ||||||||
| Depreciation and amortization | - | 9 | ||||||
| Stock-based compensation expense | 101 | 153 | ||||||
| Amortization of premium on marketable debt securities | 34 | 6 | ||||||
| Interest income from short-term deposits | (48 | ) | (5 | ) | ||||
| Loss (gain) from realization of marketable debt securities | (19 | ) | 1 | |||||
| interest income from loan to associate | (10 | ) | - | |||||
| Finance expenses | - | 1 | ||||||
| Finance expenses related to SEPA (*) | 20 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease in other receivables | 225 | 226 | ||||||
| Decrease in trade payables | - | (496 | ) | |||||
| Decrease in other payables | (366 | ) | (448 | ) | ||||
| Net cash used in operating activities | (1,167 | ) | (1,830 | ) | ||||
| Cash flow from investing activities | ||||||||
| Purchase of available for sale securities | (1,032 | ) | (898 | ) | ||||
| Investment in short term deposits | - | (375 | ) | |||||
| Consideration from sale of available for sale securities | 801 | 1,705 | ||||||
| Net cash provided by investing activities | (231 | ) | 432 | |||||
| Cash flow from financing activities | ||||||||
| Issuance of ordinary shares in relation to ATM (**) | 1,439 | - | ||||||
| Issuance of ordinary shares in relation to SEPA (*) | 75 | - | ||||||
| Net cash provided by financing activities | 1,514 | - | ||||||
| Increase (decrease) in cash and cash equivalents and restricted cash | 116 | (1,398 | ) | |||||
| Cash and cash equivalents and restricted cash at the beginning of the period | 4,773 | 2,978 | ||||||
| Cash and cash equivalents and restricted cash at the end of the period | $ | 4,889 | $ | 1,580 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash received from interest | $ | 171 | $ | 112 | ||||
CONTACT:
Guy Nehemya,
Chief Operating Officer,
Galmed Pharmaceuticals Ltd.,
investor.relations@galmedpharma.com,
+972-3-693-8448